Feng Jiang

Feng Jiang


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2018 in BioMed Research International
Verified
Journal Article
Open access
PDF file
LYLi-Li Yu
Li-Li Yu
JZJing Zhu
Jing Zhu
JLJin-Xia Liu
Jin-Xia Liu
FJFeng Jiang
Feng Jiang
WNWen-Kai Ni
Wen-Kai Ni
MXMingbing Xiao
Mingbing Xiao
Exosomes are discrete populations of small (40-200 nm in diameter) membranous vesicles that are released into the extracellular space by most cell types, eventually accumulating in the circulation. As molecular messengers, exosomes exert a broad array of vital physiologic functions by transporting information between different cell types. Because of these functional properties, they may have potential as biomarker sources for prognostic and diagnostic disease. Recent research has found that exosomes have potential to be utilized as drug delivery agents for therapeutic targets. However, basic researches on exosomes and researches on their therapeutic potential both require the existence of effective and rapid methods for their separation from human samples. In the current absence of a standardized method, there are several methods available for the separation of exosomes, but very few studies have previously compared the efficiency and suitability of these different methods. This review summarized and compared the available traditional and novel methods for the extraction of exosomes from human samples and considered their advantages and disadvantages for use in clinical laboratories and point-of-care settings.

1 May 2017 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Closed access
JLJinxia Liu
Jinxia Liu
CLCuihua Lu
Cuihua Lu
MXMingbing Xiao
Mingbing Xiao
FJFeng Jiang
Feng Jiang
LQLishuai Qu
Lishuai Qu
RNRunzhou Ni
Runzhou Ni

25 February 2012 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
LXLing Xie
Ling Xie
WNWen-Kai Ni
Wen-Kai Ni
XCXu-Dong Chen
Xu-Dong Chen
MXMingbing Xiao
Mingbing Xiao
BCBu-You Chen
Bu-You Chen
RNRunzhou Ni
Runzhou Ni

24 January 2014 in International Journal of Molecular Medicine
Verified
Journal Article
Closed access
PDF file
YJYi-Fei Ji
Yi-Fei Ji
HHHua Huang
Hua Huang
FJFeng Jiang
Feng Jiang
RNRunzhou Ni
Runzhou Ni
MXMingbing Xiao
Mingbing Xiao
The occurrence and development of pancreatic cancer is a complex process convoluted by multi-pathogenies, multi-stages and multi-factors. S100 proteins are members of the S100 family that regulate multiple cellular pathways related to pancreatic cancer progression and metastasis. S100 proteins have a broad range of intracellular and extracellular functions, including the regulation of protein phosphorylation and enzyme activity, calcium homeostasis and the regulation of cytoskeletal components and transcriptional factors. S100 proteins interact with receptor for advanced glycation end-products (RAGE), p53 and p21, which play a role in the degradation of the extracellular matrix (ECM) and metastasis, and also interact with cytoskeletal proteins and the plasma membrane in pancreatic cancer progression and metastasis. S100A11 and S100P are significant tumor markers for pancreatic cancer and unfavorable predictors for the prognosis of patients who have undergone surgical resection. Recently, S100A2 has been suggested to be a negative prognostic biomarker in pancreatic cancer, and the expression of S100A6 may be an independent prognostic impact factor. The expression of S100A4 and S100P is associated with drug resistance, differentiation, metastasis and clinical outcome. This review summarizes the role and significance of the S100 family signaling network and related proteins in pancreatic cancer.

1 July 2011 in Pancreas
Verified
Journal Article
Closed access
XLXiaoyan Li
Xiaoyan Li
RNRunzhou Ni
Runzhou Ni
JCJianhua Chen
Jianhua Chen
ZLZhaoxiu Liu
Zhaoxiu Liu
MXMingbing Xiao
Mingbing Xiao
CLCuihua Lu
Cuihua Lu
Objectives: To investigate the expression of Igγ-1 chain C region (IGHG1) in human pancreatic carcinomas and determine the biological function of IGHG1 expression in immune evasion mechanisms. Methods: Comparative proteomic analysis was used to detect the differential expression of IGHG1 in human pancreatic cancer tissues versus adjacent noncancerous tissues, followed by confirmatory tests including quantitative real-time reverse transcription-polymerase chain reaction, Western blot analysis, immunohistochemistry, and immunofluorescence. A murine pancreatic tumor model was established by transplantation of IGHG1-overexpressing Panc02 cells. The cytotoxic responses of natural killer (NK) cells were assessed with a lactate dehydrogenase release assay. Results: Igγ-1 chain C region was found to be present in human pancreatic cancer tissues but nearly absent or expressed lower in adjacent noncancerous tissues. In the murine pancreatic tumor model, the tumor growth was significantly accelerated from day 12 to 20 after tumor injection, and the survival time of animals was decreased. Blockage of IGHG1 led to retarded tumor growth and improved survival. The cytotoxicity assay revealed that IGHG1 downregulated the cytotoxic activity of NK cells through inhibition of antibody-dependent cellular cytotoxicity function. Conclusions: The presence of IGHG1 in pancreatic cancer cells might constitute an important element responsible for tumor cell proliferation and immune evasion mechanisms. Abbreviations: IGHG1 - Igγ-1 chain C region, ADCC - antibody-dependent cellular cytotoxicity, NK cells - natural killer cells, PCR - polymerase chain reaction, LDH - lactate dehydrogenase, CH - constant region of heavy chain

13 September 2011 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
MXMingbing Xiao
Mingbing Xiao
FJFeng Jiang
Feng Jiang
WNWen-Kai Ni
Wen-Kai Ni
BCBu-You Chen
Bu-You Chen
CLCui-Hua Lu
Cui-Hua Lu
RNRunzhou Ni
Runzhou Ni